Wednesday, May 15, 2019
Iconic Therapeutics is using Zymelink Tech for first ADC
Iconic is going after Tissue Factor targets in oncology, and their molecule ICON-2 is their first ADC product expected to head to the clinic.
Zymeworks is starting to make some waves. Is this a company to keep an eye on?
Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics